skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A review of ropinirole prolonged release in Parkinson’s disease

Review

(3608) Views  (929) Full article downloads

Authors: Muhammad M Nashatizadeh, Kelly E Lyons, Rajesh Pahwa

Published Date April 2009 Volume 2009:4 Pages 179 - 186
DOI: http://dx.doi.org/10.2147/CIA.S3358

Muhammad M Nashatizadeh, Kelly E Lyons, Rajesh Pahwa

Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA

Abstract: Ropinirole prolonged release is a once-daily, 24-hour formulation of ropinirole, a non-ergot dopamine agonist. It is approved as monotherapy and as an adjunct to levodopa in the treatment of Parkinson’s disease (PD). Several potential advantages of ropinirole prolonged release compared to the immediate release formulation include maintaining more consistent dopaminergic activity with steadier plasma levels, increased tolerability, greater compliance from a simpler once-daily dosing regimen and ease in dose titration. In a randomized, double-blind, non-inferiority, crossover study, ropinirole prolonged release was shown to have comparable efficacy and tolerability to immediate release ropinirole in early PD patients, with significantly greater compliance. Subjects were converted overnight between ropinirole formulations without loss of efficacy and with good tolerability. In a randomized, double-blind, placebo-controlled study in advanced PD, daily “off” time was reduced by an average of 2.1 hours with ropinirole prolonged release compared to 0.4 hours with placebo. Patients on ropinirole prolonged release were also more likely to require less daily levodopa. Ropinirole prolonged release is well tolerated with a similar adverse effect profile to other non-ergot dopamine agonists. The most common adverse effects include dyskinesia, nausea, dizziness, hallucinations, somnolence, abdominal pain or discomfort and orthostatic hypotension. Ropinirole prolonged release is a safe and effective treatment option for both early and advanced PD. This manuscript briefly reviews the current pharmacological treatment options for PD and provides a more detailed review of the currently available data regarding ropinirole prolonged release as a treatment option for PD.

Keywords: ropinirole prolonged release, ropinirole PR, dopamine agonist, Parkinson’s disease, once-daily treatment








Readers of this article also read:

Classifying late-onset dementia with MRI: Is arteriosclerotic brain degeneration the most common cause of Alzheimer′s syndrome?
Update on ropinirole in the treatment of Parkinson’s disease
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Restless legs syndrome: differential diagnosis and management with pramipexole
Ropinirole in restless legs syndrome and periodic limb movement disorder
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy